|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
gptkb:Schering-Plough_(2009)
gptkb:Organon_(2007)
gptkb:Serono_(2006)
Acceleron Pharma (2021)
Afferent Pharmaceuticals (2016)
Cubist Pharmaceuticals (2014)
|
|
gptkbp:alsoKnownAs
|
gptkb:MSD
|
|
gptkbp:CEO
|
gptkb:Robert_M._Davis
|
|
gptkbp:collaboratesWith
|
gptkb:Bayer
gptkb:Moderna
gptkb:AstraZeneca
gptkb:Ridgeback_Biotherapeutics
|
|
gptkbp:founded
|
1891
|
|
gptkbp:founder
|
gptkb:George_Merck
|
|
gptkbp:hasChineseName
|
gptkb:默沙东
|
|
gptkbp:headquartersLocation
|
gptkb:Kenilworth,_New_Jersey,_USA
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
默沙东
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:listedOn
|
gptkb:Dow_Jones_Industrial_Average
gptkb:Fortune_500
gptkb:S&P_500
|
|
gptkbp:market
|
gptkb:China
gptkb:Europe
gptkb:Japan
gptkb:Latin_America
gptkb:United_States
gptkb:Asia-Pacific
|
|
gptkbp:netIncome
|
$7.3 billion (2023)
|
|
gptkbp:notable_drug
|
gptkb:Molnupiravir
|
|
gptkbp:notableContributor
|
gptkb:diabetes
infectious diseases
oncology
vaccines
|
|
gptkbp:numberOfEmployees
|
~69,000 (2023)
|
|
gptkbp:operatesIn
|
global
|
|
gptkbp:parentCompany
|
independent
|
|
gptkbp:products
|
gptkb:Cubicin
gptkb:Gardasil
gptkb:Invanz
gptkb:Isentress
gptkb:Januvia
gptkb:Keytruda
gptkb:Propecia
gptkb:Singulair
gptkb:Zetia
|
|
gptkbp:rank
|
top 10 global pharmaceutical companies
|
|
gptkbp:revenue
|
$59.3 billion (2023)
|
|
gptkbp:spinOff
|
gptkb:Organon_&_Co._(2021)
|
|
gptkbp:stockExchange
|
gptkb:NYSE
|
|
gptkbp:stockSymbol
|
gptkb:MRK
|
|
gptkbp:subsidiary
|
gptkb:MSD_Animal_Health
|
|
gptkbp:website
|
https://www.merck.com/
|
|
gptkbp:英文名
|
gptkb:Merck_&_Co.,_Inc.
|
|
gptkbp:bfsParent
|
gptkb:美国
|
|
gptkbp:bfsLayer
|
4
|